L-carnitine and cancer cachexia: Clinical and experimental aspects

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 1, 2011, Pages 37-44

  Silvério, Renata ^a   Laviano, Alessandro ^b   Fanelli, Filippo Rossi ^b   Seelaender, Marília ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cachexia; Cancer; Fatigue; l carnitine

Indexed keywords

C REACTIVE PROTEIN; CARNITINE; CISPLATIN; DOXORUBICIN; GLUTATHIONE; IFOSFAMIDE; MYOSIN HEAVY CHAIN; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; AEROBIC METABOLISM; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; APPETITE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; CYTOKINE PRODUCTION; DEPRESSION; DRUG SAFETY; ENERGY METABOLISM; FATIGUE; GENE EXPRESSION; HEMODIALYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEAN BODY WEIGHT; LIPID METABOLISM; LOW DRUG DOSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; SLEEP DISORDER; VOMITING;

EID: 82955174476     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0017-7     Document Type: Review

References (90)

1. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol. 1997; 24: 277-87.
2. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol. 2000; 27: 64-8.
3. Davis MP, Dickerson D. Cachexia and anorexia: cancer's covert killer. Support Care Cancer. 2000; 8: 180-7.
4. Barber MD, Ross JA, Fearon KC. Cancer cachexia. Surg Oncol. 1999; 8: 133-41.
5. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010; 1: 1-5.
6. Argilés JM, Alvarez B, López-Soriano FJ. The metabolic basis of cancer cachexia. Med Res Ver. 1997; 17: 477-98.
7. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010; 1: 129-33.
8. Argilés JM, Garcia-Martínez C, Llovera M, López-Soriano FJ. The role of cytokines in muscle wasting: its relation with cancer cachexia. Med Res Rev. 1992; 12: 637-52.
9. Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009; 89: 381-410.
10. Durham WJ, Dillon EL, Sheffield-Moore M. Inflammatory burden and amino acid metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2009; 12: 72-7.
11. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-43.
12. Pajak B, Orzechowska S, Pijet B, Pijet M, Pogorzelska A, Gajkowska B, et al. Crossroads of cytokine signaling-the chase to stop muscle cachexia. J Physiol Pharmacol. 2008; 59: 251-64.
13. Orzechowski A, Ostaszewski P, Brodnicka A, et al. Excess of glucocorticoids impairs whole body antioxidant status in young rats. Relation to the effect of dexamethasone in soleus muscle and spleen. Horm Metab Res. 2000; 32: 174-80.
14. Bremer J. Carnitine-metabolism and functions. Physiol Rev. 1983; 63: 1420-80.
15. Rebouche CJ. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults. Metabolism. 1991; 40: 1305-10.
16. Mitwalli AH, Al-Wakeel JS, Alam A, Tarif N, Abu-Aisha H, Rashed M, et al. L-carnitine supplementation in hemodialysis patients. Saudi J Kidney Dis Transplant. 2005; 16: 17-22.
17. Visarius TN, Stucki JW, Lauterburg BH. Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats. J Pharmacol Exp Ther. 1999; 289: 820-4.
18. Lancaster CS, Hu C, Franke RM, Filipski KK, Orwick SJ, Chen Z, et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res. 2010; 16: 4789-99.
19. Winter SC, Szabo-Aczel S, Curry CJ, Hutchinson HT, Hogue R, Shug A. Plasma carnitine deficiency. Clinical observations in 51 pediatric patients. Am J Dis Child. 1987; 141: 660-5.
20. Dodson WL, Sachan DS, Krauss S, Hanna W. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr. 1989; 8: 133-42.
21. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, et al. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002; 86: 1854-7.
22. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann NY Acad Sci. 2004; 1033: 168-76.
23. Vinci E, Rampello E, Zanoli L, Oreste G, Pistone G, Malaguarnera M. Serum carnitine levels in patients with tumoral cachexia. Eur J Intern Med. 2005; 16: 419-23.
24. Malaguarnera M, Risino C, Gargante MP, Oreste G, Barone G, Tomasello AV, et al. Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol. 2006; 12: 4541-5.
25. Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol. 2009; 31: 664-9.
26. Evangeliou A, Vlassopoulos D. Carnitine metabolism and deficit-when supplementation is necessary? Curr Pharm Biotechnol. 2003; 4: 211-9.
27. Laviano A, Meguid MM, Guijarro A, Muscarioti M, Cascino A, Preziosa I, et al. Antimyopathic effects of carnitine and nicotine. Curr Opin Clin Nutr Metab Care. 2006; 9: 442-8.
28. Winter BK, Fiskum G, Gallo LL. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock. Br J Cancer. 1995; 72: 1173-9.
29. Li Y-P, Schwartz RJ. TNF-α regulates early differentiation of C2C12 myoblasts in an autocrine fashion. FASEB J. 2001; 15: 1413-5.
30. van Royen M, Carbó N, Busquets S, Alvarez B, Quinn LS, López-Soriano FJ, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun. 2000; 270: 533-7.
31. Busquets S, Deans C, Figueras M, Moore-Carrasco R, López-Soriano FJ, Fearon KC, et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr. 2007; 26: 614-8.
32. Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res. 1998; 4: 1743-8.
33. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001; 21: 1335-58.
34. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988; 167: 1211-27.
35. Garcia-Martinez C, Lopez-Soriano FJ, Argiles JM. Acute treatment with tumour necrosis factor-a induces changes in protein metabolism in rat skeletal muscle. Mol Cell Biochem. 1993; 125: 11-8.
36. Tessitore L, Costelli P, Baccino FM. Humoral mediation for cachexia in tumour-bearing rats. Br J Cancer. 1993; 67: 15-23.
37. Li Y-P, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kB activation in response to tumor necrosis factor α. FASEB J. 1998; 12: 871-80.
38. Dalla Libera L, Sabbadini R, Renken C, Ravara B, Sandri M, Betto R, et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol. 2001; 33: 1871-8.
39. Sabbadini RA, Danieli-Betto D, Betto R. The role of sphingolipids in the control of skeletal muscle function: a review. Ital J Neurol Sci. 1999; 20: 423-30.
40. Figueras M, Busquets S, Carbó N, Almendro V, Argilés JM, López-Soriano FJ. Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue. Int J Oncol. 2005; 27: 855-60.
41. Ramamoorthy S, Donohue M, Buck M. Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. Am J Physiol Endocrinol Metab. 2009; 297: 392-401.
42. Brass EP. Supplemental carnitine and exercise. Am J Clin Nutr. 2000; 72: 618S-23S.
43. Spagnoli LG, Palmieri G, Mauriello A, Vacha GM, D'Iddio S, Giorcelli G, et al. Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle. Nephron. 1990; 55: 16-23.
44. Giovenali P, Fenocchio D, Montanari G, Cancellotti C, D'Iddio S, Buoncristiani U, et al. Selective trophic effect of L-carnitine in type I and IIa skeletal muscle fibers. Kidney Int. 1994; 46: 1616-9.
45. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso Mr, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer. 2002; 98: 84-91.
46. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, et al. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol. 2003; 22: 17-28.
47. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Mudu MC, et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med. 2001; 79: 406-14.
48. Laviano A, Meguid MM, Preziosa I, Rossi Fanelli F. Oxidative stress and wasting in cancer. Curr Opin Clin Nutr Metab Care. 2007; 10: 449-56.
49. Reid MB. Nitric oxide, reactive oxygen species, and skeletal muscle contraction. Med Sci Sports Exerc. 2001; 33: 371-6.
50. Barreiro E, de la Puente B, Busquets S, López-Soriano FJ, Gea J, Argilés JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 2005; 579: 1646-52.
51. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002; 180: 69-74.
52. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. 1999; 19: 1721-8.
53. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis. 2006; 22: 223-32.
54. Powers SK, Kavazis AN, McClung JM. Oxidative stress and disuse muscle atrophy. J Appl Physiol. 2007; 102: 2389-97.
55. Breitkreutz R, Babylon A, Hack V, Schuster K, Tokus M, Böhles H, et al. Effect of carnitine on muscular glutamate uptake and intramuscular glutathione in malignant diseases. Br J Cancer. 2000; 82: 399-403.
56. Ushmorov A, Hack V, Dröge W. Differential reconstitution of mitochondrial respiratory chain activity and plasma redox state by cysteine and ornithine in a model of cancer cachexia. Cancer Res. 1999; 59: 3527-34.
57. Hack V, Gross A, Kinscherf R, Bockstette M, Fiers W, Berke G, et al. Abnormal glutathione and sulfate levels after interleukin 6 treatment and in tumor-induced cachexia. FASEB J. 1996; 10: 1219-26.
58. Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, et al. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006; 22: 136-45.
59. Fatouros IG, Douroudos I, Panagoutsos S, Pasadakis P, Nikolaidis MG, Chatzinikolaou A, Sovatzidis A, Michailidis Y, Jamurtas AZ, Mandalidis D, Taxildaris K, Vargemezis V. L-carnitine Effects on Oxidative Stress Responses in Patients With Renal Disease. Med Sci Sports Exerc 2010 [Epub ahead of print].
60. Sitta A, Barschak AG, Deon M, de Mari JF, Barden AT, Vanzin CS, et al. L-carnitine blood levels and oxidative stress in treated phenylketonuric patients. Cell Mol Neurobiol. 2009; 29: 211-8.
61. Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-Carnitine Supplementation to Diet: A New Tool in Treatment of Nonalcoholic Steatohepatitis-A Randomized and Controlled Clinical Trial. Am J Gastroenterol. 2010 [Epub ahead of print].
62. Mansour HH. Protective role of carnitine ester against radiation-induced oxidative stress in rats. Pharmacol Res. 2006; 54: 165-71.
63. Shaker ME, Houssen ME, Abo-Hashem EM, Ibrahim TM. Comparison of vitamin E, L-carnitine and melatonin in ameliorating carbon tetrachloride and diabetes induced hepatic oxidative stress. J Physiol Biochem. 2009; 65: 225-33.
64. Augustyniak A, Skrzydlewska E. L-Carnitine in the lipid and protein protection against ethanol-induced oxidative stress. Alcohol. 2009; 43: 217-23.
65. Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, et al. Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle. 2010; 1: 177-85.
66. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003; 98: 1786-801.
67. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. Oncologist. 2007; 1: 43-51.
68. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncol. 1999; 4: 1-10.
69. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol. 2000; 182: 339-50.
70. Neri B, Cini-Neri G, Bartalucci S, Bandinelli M. Protective effect of L-carnitine on cardiac metabolic damage induced by doxorubicin in vitro. Anticancer Res. 1986; 6: 659-62.
71. Brady LJ, Brady OS. Hepatic and cardiac carnitine palmitoytransferase activity: effects of adriamycin and galactosamine. Biochem Pharmacol. 1987; 36: 3419-23.
72. Kashfi K, Israel M, Sweatman TW, Seshadri R, Cook GA. Inhibition of mitochondrial carnitine palmitoytransferases by adriamycin and adriamycin analogues. Biochem Pharmacol. 1990; 40: 1441-8.
73. Velasco G, Sanchez C, Geelen MJ, Guzman M. Are cytoskeletal components involved in the control of hepatic carnitine palmitoytransferase I activity? Biochem Biophys Res Commun. 1996; 224: 754-9.
74. Visarius TM, Bahler H, Kupfer A, Cerny T, Lauterburg BH. Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos. 1998; 26: 193-6.
75. Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, et al. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage. 2006; 32: 551-9.
76. Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition. 2008; 24: 305-13.
77. Steffen BT, Lees SJ, Booth FW. Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. J Appl Physiol. 2008; 105: 1950-8.
78. Miguel-Carrasco JL, Mate A, Monserrat MT, Arias JL, Aramburu O, Vázquez CM. The role of inflammatory markers in the cardioprotective effect of L-carnitine in L-NAME-induced hypertension. Am J Hypertens. 2008; 21: 1231-7.
79. De Simone C, Tzantzoglou S, Famularo G, Moretti S, Paoletti F, Vullo V, et al. High dose L-carnitine improves immunologic and metabolic parameters in AIDS patients. Immunopharmacol Immunotoxicol. 1993; 15: 1-12.
80. Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr. 2005; 15: 225-30.
81. Duranay M, Akay H, Yilmaz FM, Senes M, Tekeli N, Yücel D. Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients. Nephrol Dial Transplant. 2006; 21: 3211-4.
82. Izgüt-Uysal VN, Aǧaç A, Derin N. Effect of L-carnitine on carrageenan-induced inflammation in aged rats. Gerontology. 2003; 49: 287-92.
83. Alesci S, De Martino MU, Mirani M, Benvenga S, Trimarchi F, Kino T, et al. L-carnitine: A nutritional modulator of glucocorticoid receptor functions. FASEB J. 2003; 17: 1553-5.
84. Yamashita AS, Lira FS, Rosa JC, Paulino EC, Brum PC, Negrão CE, Dos Santos RV, Batista ML Jr, Oller do Nascimento C, Oyama LM, Seelaender M. Depot-specific modulation of adipokine levels in rat adipose tissue by diet-induced obesity: The effect of aerobic training and energy restriction. Cytokine 2010 [Epub ahead of print].
85. Rosa Neto JC, Lira FS, Oyama LM, Zanchi NE, Yamashita AS, Batista Jr ML, et al. Exhaustive exercise causes na anti-inflammatory effect in skeletal muscle and a pro-inflammatory effect in adipose tissue in rats. Eur J Appl Physiol. 2009; 106: 697-704.
86. Lira FS, Rosa JC, Zanchi NE, Yamashita AS, Lopes RD, Lopes AC, et al. Regulation of inflammation in the adipose tissue in cancer cachexia: effect of exercise. Cell Biochem Funct. 2009; 27: 71-5.
87. Machado AP, Costa Rosa LF, Seelaender MC. Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell Tissue Res. 2004; 318: 503-14.
88. Nachiappan V, Curtiss D, Corkey BE, Kilpatrick L. Cytokines inhibit fatty acid oxidation in isolated rat hepatocytes: synergy among TNF, IL-6, and IL-1. Shock. 1994; 1: 123-9.
89. Laviano A, Inui A, Marks DL, Meguid MM, Pichard C, Fanelli FR, et al. Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab. 2008; 295: E1000-8.
90. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2010; 1: 7-8.